Cargando…
Correlation and diagnostic performance of the prostate-specific antigen level with the diagnosis, aggressiveness, and bone metastasis of prostate cancer in clinical practice
PURPOSE: The common tool for diagnosing prostate cancer is serum prostate-specific antigen (PSA) testing and digital rectal examination, but the disadvantage of the high sensitivity and low specificity of PSA testing in the diagnosis of prostate cancer is a problem in clinical practice. We studied t...
Autores principales: | , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Asian Pacific Prostate Society (APPS)
2014
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4186957/ https://www.ncbi.nlm.nih.gov/pubmed/25325025 http://dx.doi.org/10.12954/PI.14054 |
_version_ | 1782338136581341184 |
---|---|
author | Lojanapiwat, Bannakij Anutrakulchai, Wisan Chongruksut, Wilaiwan Udomphot, Chaichawan |
author_facet | Lojanapiwat, Bannakij Anutrakulchai, Wisan Chongruksut, Wilaiwan Udomphot, Chaichawan |
author_sort | Lojanapiwat, Bannakij |
collection | PubMed |
description | PURPOSE: The common tool for diagnosing prostate cancer is serum prostate-specific antigen (PSA) testing and digital rectal examination, but the disadvantage of the high sensitivity and low specificity of PSA testing in the diagnosis of prostate cancer is a problem in clinical practice. We studied the correlation and diagnostic performance of the PSA level with cancer diagnosis, aggressiveness of prostate cancer (Gleason score>7), and bone metastasis. METHODS: A total 1,116 patients who underwent transrectal ultrasound and prostate biopsy were retrospectively studied. The patients were divided into subgroups by baseline PSA level as follows: ≤4, 4.1–10, 10.1–20, 20.1–50, 50.1–100, and >100 ng/mL. The area under the receiver operating characteristic curve (AuROC), sensitivity, specificity, positive predictive value, negative predictive value, positive likelihood ratio, and negative likelihood ratio of each PSA level were evaluated for correlation and diagnostic performance with positive biopsy, Gleason score for aggressiveness, and bone metastasis. RESULTS: A positive biopsy result was found in 395 patients (35.39%). The PSA level corresponded well with the diagnosis of prostate cancer and a positive bone scan but moderately well with Gleason score as shown by AuROC for diagnosis of prostate cancer (0.82), positive bone scan (0.88), and Gleason score>7 (0.78). The specificity of a PSA level of 4.1–10, 10.1–20, 21.1–50, 50.1–100, and >100 ng/mL in the diagnosis prostate cancer was 9.3, 55.5, 87.5, 98.2, and 99.7, respectively. CONCLUSIONS: The data showed a strong correlation of PSA level with tumor diagnosis, tumor aggressiveness, and bone metastasis. The prevalence of prostate cancer in this cohort was 35.39%. The chance of diagnosis of prostate cancer was greater than that for benign prostatic hyperplasia when the PSA level was higher than 20 ng/mL. |
format | Online Article Text |
id | pubmed-4186957 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2014 |
publisher | Asian Pacific Prostate Society (APPS) |
record_format | MEDLINE/PubMed |
spelling | pubmed-41869572014-10-16 Correlation and diagnostic performance of the prostate-specific antigen level with the diagnosis, aggressiveness, and bone metastasis of prostate cancer in clinical practice Lojanapiwat, Bannakij Anutrakulchai, Wisan Chongruksut, Wilaiwan Udomphot, Chaichawan Prostate Int Original Article PURPOSE: The common tool for diagnosing prostate cancer is serum prostate-specific antigen (PSA) testing and digital rectal examination, but the disadvantage of the high sensitivity and low specificity of PSA testing in the diagnosis of prostate cancer is a problem in clinical practice. We studied the correlation and diagnostic performance of the PSA level with cancer diagnosis, aggressiveness of prostate cancer (Gleason score>7), and bone metastasis. METHODS: A total 1,116 patients who underwent transrectal ultrasound and prostate biopsy were retrospectively studied. The patients were divided into subgroups by baseline PSA level as follows: ≤4, 4.1–10, 10.1–20, 20.1–50, 50.1–100, and >100 ng/mL. The area under the receiver operating characteristic curve (AuROC), sensitivity, specificity, positive predictive value, negative predictive value, positive likelihood ratio, and negative likelihood ratio of each PSA level were evaluated for correlation and diagnostic performance with positive biopsy, Gleason score for aggressiveness, and bone metastasis. RESULTS: A positive biopsy result was found in 395 patients (35.39%). The PSA level corresponded well with the diagnosis of prostate cancer and a positive bone scan but moderately well with Gleason score as shown by AuROC for diagnosis of prostate cancer (0.82), positive bone scan (0.88), and Gleason score>7 (0.78). The specificity of a PSA level of 4.1–10, 10.1–20, 21.1–50, 50.1–100, and >100 ng/mL in the diagnosis prostate cancer was 9.3, 55.5, 87.5, 98.2, and 99.7, respectively. CONCLUSIONS: The data showed a strong correlation of PSA level with tumor diagnosis, tumor aggressiveness, and bone metastasis. The prevalence of prostate cancer in this cohort was 35.39%. The chance of diagnosis of prostate cancer was greater than that for benign prostatic hyperplasia when the PSA level was higher than 20 ng/mL. Asian Pacific Prostate Society (APPS) 2014-09 2014-07-30 /pmc/articles/PMC4186957/ /pubmed/25325025 http://dx.doi.org/10.12954/PI.14054 Text en Copyright © 2014 Asian Pacific Prostate Society (APPS) This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0/) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Original Article Lojanapiwat, Bannakij Anutrakulchai, Wisan Chongruksut, Wilaiwan Udomphot, Chaichawan Correlation and diagnostic performance of the prostate-specific antigen level with the diagnosis, aggressiveness, and bone metastasis of prostate cancer in clinical practice |
title | Correlation and diagnostic performance of the prostate-specific antigen level with the diagnosis, aggressiveness, and bone metastasis of prostate cancer in clinical practice |
title_full | Correlation and diagnostic performance of the prostate-specific antigen level with the diagnosis, aggressiveness, and bone metastasis of prostate cancer in clinical practice |
title_fullStr | Correlation and diagnostic performance of the prostate-specific antigen level with the diagnosis, aggressiveness, and bone metastasis of prostate cancer in clinical practice |
title_full_unstemmed | Correlation and diagnostic performance of the prostate-specific antigen level with the diagnosis, aggressiveness, and bone metastasis of prostate cancer in clinical practice |
title_short | Correlation and diagnostic performance of the prostate-specific antigen level with the diagnosis, aggressiveness, and bone metastasis of prostate cancer in clinical practice |
title_sort | correlation and diagnostic performance of the prostate-specific antigen level with the diagnosis, aggressiveness, and bone metastasis of prostate cancer in clinical practice |
topic | Original Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4186957/ https://www.ncbi.nlm.nih.gov/pubmed/25325025 http://dx.doi.org/10.12954/PI.14054 |
work_keys_str_mv | AT lojanapiwatbannakij correlationanddiagnosticperformanceoftheprostatespecificantigenlevelwiththediagnosisaggressivenessandbonemetastasisofprostatecancerinclinicalpractice AT anutrakulchaiwisan correlationanddiagnosticperformanceoftheprostatespecificantigenlevelwiththediagnosisaggressivenessandbonemetastasisofprostatecancerinclinicalpractice AT chongruksutwilaiwan correlationanddiagnosticperformanceoftheprostatespecificantigenlevelwiththediagnosisaggressivenessandbonemetastasisofprostatecancerinclinicalpractice AT udomphotchaichawan correlationanddiagnosticperformanceoftheprostatespecificantigenlevelwiththediagnosisaggressivenessandbonemetastasisofprostatecancerinclinicalpractice |